Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Parmax Pharma Ltd (NSE: PARMAX), ISIN INE240T01014 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
PARMAX last traded at ₹136.40 (+1.00%), with a 52-week range of ₹22.60 to ₹136.40 (as of 21 Sep 2026).
Shareholding as of Mar 2026: promoters 30.80%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 59/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.